Compare WFG & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WFG | ALKS |
|---|---|---|
| Founded | 1955 | 1987 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.8B |
| IPO Year | N/A | 1991 |
| Metric | WFG | ALKS |
|---|---|---|
| Price | $60.29 | $28.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $93.00 | $42.85 |
| AVG Volume (30 Days) | 275.7K | ★ 2.1M |
| Earning Date | 10-22-2025 | 10-28-2025 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ 2.44 |
| EPS | N/A | ★ 2.02 |
| Revenue | ★ $5,702,000,000.00 | $1,521,338,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.45 | $24.22 |
| P/E Ratio | ★ N/A | $14.13 |
| Revenue Growth | N/A | ★ 1.08 |
| 52 Week Low | $57.34 | $25.17 |
| 52 Week High | $94.18 | $36.45 |
| Indicator | WFG | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 45.93 | 40.75 |
| Support Level | $59.21 | $27.81 |
| Resistance Level | $63.02 | $29.35 |
| Average True Range (ATR) | 1.54 | 0.91 |
| MACD | 0.17 | -0.05 |
| Stochastic Oscillator | 32.13 | 13.40 |
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.